Shorter, E. A History of Psychiatry: From the Era of the Asylum to the Age of Prozac. John Wiley & Sons, 1997.
Leff, JP, Wing, JK. Trial of maintenance therapy in schizophrenia. BMJ
1971; 3: 599–604.
Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Salanti, G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet
2012; 379: 2063–71.
Moncrieff, J. Antipsychotic maintenance treatment: time to rethink?
2015; 12: e1001861.
Walker, ER, McGee, RE, Druss, BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry
2015; 72: 334–41.
Brown, S, Kim, M, Mitchell, C, Inskip, H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry
2010; 196: 116–21.
Hoang, U, Stewart, R, Goldacre, MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. BMJ
2011; 343: d5422.
Saha, S, Chant, D, McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?
Arch Gen Psychiatry
2007; 64: 1123–31.
Lawrence, D, Kisely, S, Pais, J. The epidemiology of excess mortality in people with mental illness. Can J Psychiatry
2010; 55: 752–60.
Laursen, TM, Nordentoft, M, Mortensen, PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol
2014; 10: 425–48.
Frommeyer, G, Eckardt, L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol
2016; 13: 36–47.
Ray, WA, Chung, CP, Murray, KT, Hall, K, Stein, CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med
2009; 360: 225–35.
Henderson, DC, Vincenzi, B, Andrea, NV, Ulloa, M, Copeland, PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry
2015; 2: 452–64.
Stahl, SM, Mignon, L, Meyer, JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Acta Psychiatr Scand
2009; 119: 171–9.
De Hert, M, Detraux, J, van Winkel, R, Yu, W, Correll, CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol
2012; 8: 114–26.
Torniainen, M, Mittendorfer-Rutz, E, Tanskanen, A, Bjorkenstam, C, Suvisaari, J, Alexanderson, K, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull
2015; 41: 656–63.
Mace, S, Dzahini, O, Cornelius, V, Anthony, D, Stewart, R, Taylor, D. Antipsychotic use and unexpected death: a hospital-based case-control study. Acta Psychiatr Scand
2015; 132: 479–88.
Murray, RM, Lewis, SW. Is schizophrenia a neurodevelopmental disorder?
BMJ (Clin Res Ed)
1987; 295: 681–2.
van Haren, NE, Cahn, W, Hulshoff Pol, HE, Kahn, RS. Schizophrenia as a progressive brain disease. Eur Psychiatry
2008; 23: 245–54.
Navari, S, Dazzan, P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med
2009; 39: 1763–77.
Moncrieff, J, Leo, J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med
2010; 40: 1409–22.
Zipursky, RB, Reilly, TJ, Murray, RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull
2013; 39: 1363–72.
Vita, A, De Peri, L, Deste, G, Sacchetti, E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry
2012; 2: e190.
Rais, M, Cahn, W, van Haren, N, Schnack, H, Caspers, E, Hulshoff Pol, H, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry
2008; 165: 490–6.
Karama, S, Ducharme, S, Corley, J, Chouinard-Decorte, F, Starr, JM, Wardlaw, JM, et al. Cigarette smoking and thinning of the brain's cortex. Mol Psychiatry
2015; 20: 778–85.
Katon, W, Pedersen, HS, Ribe, AR, Fenger-Gron, M, Davydow, D, Waldorff, FB, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. JAMA Psychiatry
2015; 72: 612–9.
Dorph-Petersen, KA, Pierri, JN, Perel, JM, Sun, Z, Sampson, AR, Lewis, DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology
2005; 30: 1649–61.
Vernon, AC, Crum, WR, Lerch, JP, Chege, W, Natesan, S, Modo, M, et al. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs – linking magnetic resonance imaging findings to cellular pathology. Biol Psychiatry
2014; 75: 982–90.
Konopaske, GT, Dorph-Petersen, KA, Pierri, JN, Wu, Q, Sampson, AR, Lewis, DA. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology
2007; 32: 1216–23.
Vita, A, De Peri, L, Deste, G, Barlati, S, Sacchetti, E. The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biol Psychiatry
2015; 78: 403–12.
Boonstra, G, van Haren, NE, Schnack, HG, Cahn, W, Burger, H, Boersma, M, et al. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. J Clin Psychopharmacol
2011; 31: 146–53.
Vernon, AC, Natesan, S, Crum, WR, Cooper, JD, Modo, M, Williams, SC, et al. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry
2012; 71: 855–63.
AV, Terry Jr, Gearhart, DA, Warner, SE, Zhang, G, Bartlett, MG, Middlemore, ML, et al. Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience
2007; 146: 1316–32.
Terry, AV Jr, Hill, WD, Parikh, V, Evans, DR, Waller, JL, Mahadik, SP. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology
2002; 164: 360–8.
Gur, RE, Turetsky, BI, Bilker, WB, Gur, RC. Reduced gray matter volume in schizophrenia. Arch Gen Psychiatry
1999; 56: 905–11.
Taylor, M, Cavanagh, J, Hodgson, R, Tiihonen, J. Examining the effectiveness of antipsychotic medication in first-episode psychosis. J Psychopharmacol
2012; 26: 27–32.
Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Davis, JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev
2012; 5: CD008016.
Harrow, M, Jobe, TH, Faull, RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med
2014; 44: 3007–16.
Moilanen, J, Haapea, M, Miettunen, J, Jaaskelainen, E, Veijola, J, Isohanni, M, et al. Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication – a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur Psychiatry
2013; 28: 53–8.
Morgan, C, Lappin, J, Heslin, M, Donoghue, K, Lomas, B, Reininghaus, U, et al. Reappraising the long-term course and outcome of psychotic disorders: the ÆSOP-10 study. Psychol Med
2014; 44: 2713–26.
Wunderink, L, Nienhuis, FJ, Sytema, S, Slooff, CJ, Knegtering, R, Wiersma, D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry
2007; 68: 654–61.
Wunderink, L, Nieboer, RM, Wiersma, D, Sytema, S, Nienhuis, FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry
2013; 70: 913–20.
McGorry, P, Alvarez-Jimenez, M, Killackey, E. Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry
2013; 70: 898–900.
Howes, OD, Murray, RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet
2014; 383: 1677–87.
Smith, RC, Davis, JM. Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. Life Sci
1976; 19: 725–31.
Grace, AA. Dopamine system dysregulation and the pathophysiology of schizophrenia: insights from the methylazoxymethanol acetate model. Biol Psychiatry
Samaha, AN, Seeman, P, Stewart, J, Rajabi, H, Kapur, S. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci
2007; 27: 2979–86.
Ginovart, N, Wilson, AA, Hussey, D, Houle, S, Kapur, S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal 11Craclopride PET study in cats. Neuropsychopharmacology
2009; 34: 662–71.
Zakzanis, KK, Hansen, KT. Dopamine D2 densities and the schizophrenic brain. Schizophr Res
1998; 32: 201–6.
Howes, OD, Kambeitz, J, Kim, E, Stahl, D, Slifstein, M, Abi-Dargham, A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry
2012; 69: 776–86.
Silvestri, S, Seeman, MV, Negrete, JC, Houle, S, Shammi, CM, Remington, GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology
2000; 152: 174–80.
Konig, P, Benzer, MK, Fritzche, H. SPECT technique for visualization of cerebral dopamine D2 receptors. Am J Psychiatry
1991; 148: 1607–8.
Mizrahi, R, Agid, O, Borlido, C, Suridjan, I, Rusjan, P, Houle, S, et al. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res
2011; 131: 63–8.
Chouinard, G, Jones, BD, Annable, L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry
1978; 135: 1409–10.
Chouinard, G, Chouinard, VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom
2008; 77: 69–77.
Chouinard, G, Annable, L, Ross-Chouinard, A. Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull
1986; 22: 891–6.
Tenback, DE, van Harten, PN, Slooff, CJ, van Os, J. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr Psychiatry
2007; 48: 436–40.
Carpenter, WT, McGlashan, TH, Strauss, JS. The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. Am J Psychiatry
1977; 134: 14–20.
Moncrieff, J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand
2006; 114: 3–13.
Roy-Desruisseaux, J, Landry, J, Bocti, C, Tessier, D, Hottin, P, Trudel, JF. Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. Ann Pharmacother
2011; 45: e51.
Lu, ML, Pan, JJ, Teng, HW, Su, KP, Shen, WW. Metoclopramide-induced supersensitivity psychosis. Ann Pharmacother
2002; 36: 1387–90.
Seeman, P. Yes, Breast is best but taper domperidone when stopping (e-letter). Br J Gen Pract
Joyce, JN. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse
2001; 40: 137–44.
Quinn, R. Comparing rat's to human's age: how old is my rat in people years?
2005; 21: 775–7.
Corstens, D, Longden, E, McCarthy-Jones, S, Waddingham, R, Thomas, N. Emerging perspectives from the hearing voices movement: implications for research and practice. Schizophr Bull
2014; 40: S285–94.
Corstens, D, Longden, E, Rydinger, B, Bentall, R, van Os, J. Treatment of hallucinations: a comment. Psychosis
2013; 5: 98–102.
Tadokoro, S, Okamura, N, Sekine, Y, Kanahara, N, Hashimoto, K, Iyo, M. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull
2012; 38: 1012–20.
Takaesu, Y, Kishimoto, T, Murakoshi, A, Takahashi, N, Inoue, Y. Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: a prospective observational study. Psychiatry Res
2016; 236: 71–4.
Demjaha, A, Egerton, A, Murray, RM, Kapur, S, Howes, OD, Stone, JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry
2014; 75: e11–3.
Demjaha, A, Murray, RM, McGuire, PK, Kapur, S, Howes, OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry
2012; 169: 1203–10.
Suzuki, T, Kanahara, N, Yamanaka, H, Takase, M, Kimura, H, Watanabe, H, et al. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res
2015; 227: 278–82.
Oda, Y, Kanahara, N, Iyo, M. Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: the pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia. Int J Mol Sci
2015; 16: 30144–63.
Girgis, RR, Phillips, MR, Li, X, Li, K, Jiang, H, Wu, C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry
2011; 199: 281–8.
Howes, OD, Egerton, A, Allan, V, McGuire, P, Stokes, P, Kapur, S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des
2009; 15: 2550–9.
Schizophrenia Commission. The Abandoned Illness.